Live Breaking News & Updates on வளர்ச்சி ஆஃப் குவாண்டம் மரபியல்
Stay updated with breaking news from வளர்ச்சி ஆஃப் குவாண்டம் மரபியல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
(1) Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that directly targets the brain to treat difficult to treat/resistant hypertension and heart failure, announces the publication in Biomedecine &Pharmacotherapy of a new scientific peer-reviewed article reporting the efficacy of firibastat in combination with enalapril and hydrochlorothiazide in an experimental model of salt-sensitive hypertension (the DOCA-salt hypertensive rat). The article, entitled Effects of firibastat in combination with enalapril and hydrochlorothiazide on blood pressure and vasopressin release in hypertensive DOCA-salt rats is available online on the website of the journal Biomedecine -& Pharmacotherapy (Biomedicine & Pharmacotherapy - Journal - Elsevier DOI: 10.1016/j.biopha.2021.111682). The reported data demonstrate that the hypotensive effect induced in hypertensive DOCA-salt rat with a once-d ....
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Quantum Genomics Signs a Strategic Contract with Delpharm Quantum GenomicsDecember 16, 2020 GMT PARIS and NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new class of drugs acting directly on the brain to treat difficult-to-treat / resistant hypertension and heart failure, announces today that it has signed a strategic contract with Delpharm for the manufacture of the next clinical batches of firibastat tablets on an industrial scale and the establishment of production lines for future commercial batches. ....